This Arthritis Monoclonal Antibodies market report provides a comprehensive analysis of the market’s characteristics, size, and growth, including segmentation, regional and country-level breakdowns, competitive landscape, market shares, trends, and strategies. It also tracks historical and forecasted market growth across various geographies.
The arthritis monoclonal antibodies market size has grown strongly in recent years. It will grow from $58.09 billion in 2024 to $62.29 billion in 2025 at a compound annual growth rate (CAGR) of 7.2%. The growth in the historic period can be attributed to the rising prevalence of arthritis, increasing awareness of arthritis monoclonal antibodies, expanding the range of approved arthritis monoclonal antibodies, government support for research and development, and increased investment from pharmaceutical companies.
The arthritis monoclonal antibodies market size is expected to see strong growth in the next few years. It will grow to $83.76 billion in 2029 at a compound annual growth rate (CAGR) of 7.7%. The growth in the forecast period can be attributed to combination therapies, expanding indications, patient preference, and increased healthcare spending. Major trends in the forecast period include biosimilars and biobetters, targeted therapies, homecare administration, real-world evidence, cost and access considerations, and advancements in drug delivery.
The rising global prevalence of arthritis has significantly fueled the growth of the arthritis monoclonal antibody market. The Global RA Network reported that in 2021, more than 350 million people worldwide were affected by arthritis, with osteoarthritis being the most common type, followed by gout, fibromyalgia, and rheumatoid arthritis. For example, a report from Arthritis Australia in February 2024 projected that the number of Australians suffering from arthritis will rise from 4.11 million in 2025 to 5.39 million by 2040. Consequently, the increasing incidence of arthritis is propelling the growth of the arthritis monoclonal antibody market.
The increasing approvals for personalized medicines are anticipated to boost the arthritis monoclonal antibody market in the future. Personalized medicines are therapeutic products tailored specifically to individual patients, designed based on genetic, biomarker, phenotypic, or psychosocial characteristics that can help predict how a patient will respond to treatment. Monoclonal antibodies (mABs) represent a new generation of drugs that align with the personalized medicine approach, holding promise for enhancing patient outcomes and improving healthcare efficiency. For example, a report from the Personalized Medicine Coalition, a U.S.-based non-profit organization advocating for the adoption of personalized medicine, noted in February 2024 the significance of 26 newly approved personalized treatments, 19 expanded indications for existing personalized medicines, and 17 noteworthy new or expanded indications for 12 diagnostic testing products. Therefore, the rise in approvals for personalized medicines is driving growth in the arthritis monoclonal antibody market.
The evolution of therapeutic monoclonal antibody products stands as a pivotal force in advancing the arthritis monoclonal antibody market. These highly efficient, target-specific antibodies excel in treating arthritis, surpassing small molecules and peptides. The market's expansion is evident through the introduction of a multitude of monoclonal antibody drugs dedicated to arthritis treatment, signifying enhanced therapeutic options.
Leading players in the arthritis monoclonal antibody market are introducing cost-effective biosimilar versions like Hulio to ensure more accessible treatment options. Hulio, a biosimilar variant of AbbVie's Humira, a prominent rheumatoid arthritis drug, was launched by Biocon Biologics in July 2023. Priced at a 5% discount to Humira, which currently stands at $6,922 per carton, Hulio caters to conditions like rheumatoid arthritis and psoriatic arthritis, aiming to make treatment more affordable.
In May 2023, Abiogen Pharma Spa, an Italy-based pharmaceutical company, acquired EffRx Pharmaceuticals SA for $8.77 million. The acquisition of a majority stake in EffRx is consistent with Abiogen's growth strategy. It provides a springboard for their international expansion and affirms their dedication to improving osteoarticular and bone metabolism diseases. EffRx Pharmaceuticals SA is a Switzerland-based pharmaceutical company involved in treating various disorders, including arthritis.
Arthritis monoclonal antibodies represent an advanced class of biological medications specifically utilized for treating rheumatoid arthritis and immune-mediated inflammatory conditions. These medications work by inhibiting interleukin-6, a key inflammatory protein, thereby alleviating joint pain, swelling, and other inflammation-related symptoms. Additionally, they play a role in reducing the body's defense mechanism to prevent rejection of newly transplanted organs.
The primary types of drugs in this category include Remicade, Humira, Enbrel, Rituxan, Orencia, Actemra, Simponi, Cimzia, and Remsima. Remicade, for instance, is prescribed for individuals with moderately to severely active Crohn's disease who haven't responded well to other treatments. These medications find application across various conditions such as rheumatoid arthritis, osteoarthritis, psoriatic arthritis, ankylosing spondylitis, fibromyalgia, among others. Their utilization spans multiple sectors including hospitals, research institutes, and other healthcare domains.
The arthritis monoclonal antibodies market research report is one of a series of new reports that provides arthritis monoclonal antibodies market statistics, including arthritis monoclonal antibodies industry global market size, regional shares, competitors with arthritis monoclonal antibodies market share, detailed arthritis monoclonal antibodies market segments, market trends and opportunities, and any further data you may need to thrive in the arthritis monoclonal antibodies industry. This arthritis monoclonal antibodies market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
Major companies operating in the arthritis monoclonal antibodies market include Johnson & Johnson, Hoffmann-La Roche Ltd., Novartis AG, Pfizer Inc., AbbVie Inc., Amgen Inc., Genentech Inc., GlaxoSmithKline plc., AstraZeneca plc, Bristol Myers Squibb, Eli Lilly and Company, Thermo Fisher Scientific Inc., Sanofi SA, Daiichi Sankyo Company Ltd., Seattle Genetics, Teva Pharmaceutical Industries Ltd., Shanghai Junshi Biosciences Co. Ltd., GenScript Biotech Corporation, Sigma-Aldrich Co. LLC, AbGenomics Corp., ADC Therapeutics SA, Agensys Inc., Alexion Pharmaceuticals Inc., ALMAC Group Ltd., Ambrx Inc., Astellas Pharma Inc., Celgene Corporation, Celldex Therapeutics Inc., Boehringer Ingelheim International GmbH, Celltrion Inc., HanAll Biopharma Co. Ltd., Merck & Co. Inc., Mitsubishi Tanabe Pharma Corporation, Regeneron Pharmaceuticals Inc., Samsung Bioepis Co. Ltd.
North America was the largest region in the arthritis monoclonal antibodies market in 2024. The regions covered in the arthritis monoclonal antibodies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the arthritis monoclonal antibodies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.
The arthritis monoclonal antibodies market consists of sales of infliximab, adalimumab, golimumab, and certolizumab. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The arthritis monoclonal antibodies market size has grown strongly in recent years. It will grow from $58.09 billion in 2024 to $62.29 billion in 2025 at a compound annual growth rate (CAGR) of 7.2%. The growth in the historic period can be attributed to the rising prevalence of arthritis, increasing awareness of arthritis monoclonal antibodies, expanding the range of approved arthritis monoclonal antibodies, government support for research and development, and increased investment from pharmaceutical companies.
The arthritis monoclonal antibodies market size is expected to see strong growth in the next few years. It will grow to $83.76 billion in 2029 at a compound annual growth rate (CAGR) of 7.7%. The growth in the forecast period can be attributed to combination therapies, expanding indications, patient preference, and increased healthcare spending. Major trends in the forecast period include biosimilars and biobetters, targeted therapies, homecare administration, real-world evidence, cost and access considerations, and advancements in drug delivery.
The rising global prevalence of arthritis has significantly fueled the growth of the arthritis monoclonal antibody market. The Global RA Network reported that in 2021, more than 350 million people worldwide were affected by arthritis, with osteoarthritis being the most common type, followed by gout, fibromyalgia, and rheumatoid arthritis. For example, a report from Arthritis Australia in February 2024 projected that the number of Australians suffering from arthritis will rise from 4.11 million in 2025 to 5.39 million by 2040. Consequently, the increasing incidence of arthritis is propelling the growth of the arthritis monoclonal antibody market.
The increasing approvals for personalized medicines are anticipated to boost the arthritis monoclonal antibody market in the future. Personalized medicines are therapeutic products tailored specifically to individual patients, designed based on genetic, biomarker, phenotypic, or psychosocial characteristics that can help predict how a patient will respond to treatment. Monoclonal antibodies (mABs) represent a new generation of drugs that align with the personalized medicine approach, holding promise for enhancing patient outcomes and improving healthcare efficiency. For example, a report from the Personalized Medicine Coalition, a U.S.-based non-profit organization advocating for the adoption of personalized medicine, noted in February 2024 the significance of 26 newly approved personalized treatments, 19 expanded indications for existing personalized medicines, and 17 noteworthy new or expanded indications for 12 diagnostic testing products. Therefore, the rise in approvals for personalized medicines is driving growth in the arthritis monoclonal antibody market.
The evolution of therapeutic monoclonal antibody products stands as a pivotal force in advancing the arthritis monoclonal antibody market. These highly efficient, target-specific antibodies excel in treating arthritis, surpassing small molecules and peptides. The market's expansion is evident through the introduction of a multitude of monoclonal antibody drugs dedicated to arthritis treatment, signifying enhanced therapeutic options.
Leading players in the arthritis monoclonal antibody market are introducing cost-effective biosimilar versions like Hulio to ensure more accessible treatment options. Hulio, a biosimilar variant of AbbVie's Humira, a prominent rheumatoid arthritis drug, was launched by Biocon Biologics in July 2023. Priced at a 5% discount to Humira, which currently stands at $6,922 per carton, Hulio caters to conditions like rheumatoid arthritis and psoriatic arthritis, aiming to make treatment more affordable.
In May 2023, Abiogen Pharma Spa, an Italy-based pharmaceutical company, acquired EffRx Pharmaceuticals SA for $8.77 million. The acquisition of a majority stake in EffRx is consistent with Abiogen's growth strategy. It provides a springboard for their international expansion and affirms their dedication to improving osteoarticular and bone metabolism diseases. EffRx Pharmaceuticals SA is a Switzerland-based pharmaceutical company involved in treating various disorders, including arthritis.
Arthritis monoclonal antibodies represent an advanced class of biological medications specifically utilized for treating rheumatoid arthritis and immune-mediated inflammatory conditions. These medications work by inhibiting interleukin-6, a key inflammatory protein, thereby alleviating joint pain, swelling, and other inflammation-related symptoms. Additionally, they play a role in reducing the body's defense mechanism to prevent rejection of newly transplanted organs.
The primary types of drugs in this category include Remicade, Humira, Enbrel, Rituxan, Orencia, Actemra, Simponi, Cimzia, and Remsima. Remicade, for instance, is prescribed for individuals with moderately to severely active Crohn's disease who haven't responded well to other treatments. These medications find application across various conditions such as rheumatoid arthritis, osteoarthritis, psoriatic arthritis, ankylosing spondylitis, fibromyalgia, among others. Their utilization spans multiple sectors including hospitals, research institutes, and other healthcare domains.
The arthritis monoclonal antibodies market research report is one of a series of new reports that provides arthritis monoclonal antibodies market statistics, including arthritis monoclonal antibodies industry global market size, regional shares, competitors with arthritis monoclonal antibodies market share, detailed arthritis monoclonal antibodies market segments, market trends and opportunities, and any further data you may need to thrive in the arthritis monoclonal antibodies industry. This arthritis monoclonal antibodies market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
Major companies operating in the arthritis monoclonal antibodies market include Johnson & Johnson, Hoffmann-La Roche Ltd., Novartis AG, Pfizer Inc., AbbVie Inc., Amgen Inc., Genentech Inc., GlaxoSmithKline plc., AstraZeneca plc, Bristol Myers Squibb, Eli Lilly and Company, Thermo Fisher Scientific Inc., Sanofi SA, Daiichi Sankyo Company Ltd., Seattle Genetics, Teva Pharmaceutical Industries Ltd., Shanghai Junshi Biosciences Co. Ltd., GenScript Biotech Corporation, Sigma-Aldrich Co. LLC, AbGenomics Corp., ADC Therapeutics SA, Agensys Inc., Alexion Pharmaceuticals Inc., ALMAC Group Ltd., Ambrx Inc., Astellas Pharma Inc., Celgene Corporation, Celldex Therapeutics Inc., Boehringer Ingelheim International GmbH, Celltrion Inc., HanAll Biopharma Co. Ltd., Merck & Co. Inc., Mitsubishi Tanabe Pharma Corporation, Regeneron Pharmaceuticals Inc., Samsung Bioepis Co. Ltd.
North America was the largest region in the arthritis monoclonal antibodies market in 2024. The regions covered in the arthritis monoclonal antibodies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the arthritis monoclonal antibodies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.
The arthritis monoclonal antibodies market consists of sales of infliximab, adalimumab, golimumab, and certolizumab. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Arthritis Monoclonal Antibodies Market Characteristics3. Arthritis Monoclonal Antibodies Market Trends and Strategies4. Arthritis Monoclonal Antibodies Market - Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market32. Global Arthritis Monoclonal Antibodies Market Competitive Benchmarking and Dashboard33. Key Mergers and Acquisitions in the Arthritis Monoclonal Antibodies Market34. Recent Developments in the Arthritis Monoclonal Antibodies Market
5. Global Arthritis Monoclonal Antibodies Growth Analysis and Strategic Analysis Framework
6. Arthritis Monoclonal Antibodies Market Segmentation
7. Arthritis Monoclonal Antibodies Market Regional and Country Analysis
8. Asia-Pacific Arthritis Monoclonal Antibodies Market
9. China Arthritis Monoclonal Antibodies Market
10. India Arthritis Monoclonal Antibodies Market
11. Japan Arthritis Monoclonal Antibodies Market
12. Australia Arthritis Monoclonal Antibodies Market
13. Indonesia Arthritis Monoclonal Antibodies Market
14. South Korea Arthritis Monoclonal Antibodies Market
15. Western Europe Arthritis Monoclonal Antibodies Market
16. UK Arthritis Monoclonal Antibodies Market
17. Germany Arthritis Monoclonal Antibodies Market
18. France Arthritis Monoclonal Antibodies Market
19. Italy Arthritis Monoclonal Antibodies Market
20. Spain Arthritis Monoclonal Antibodies Market
21. Eastern Europe Arthritis Monoclonal Antibodies Market
22. Russia Arthritis Monoclonal Antibodies Market
23. North America Arthritis Monoclonal Antibodies Market
24. USA Arthritis Monoclonal Antibodies Market
25. Canada Arthritis Monoclonal Antibodies Market
26. South America Arthritis Monoclonal Antibodies Market
27. Brazil Arthritis Monoclonal Antibodies Market
28. Middle East Arthritis Monoclonal Antibodies Market
29. Africa Arthritis Monoclonal Antibodies Market
30. Arthritis Monoclonal Antibodies Market Competitive Landscape and Company Profiles
31. Arthritis Monoclonal Antibodies Market Other Major and Innovative Companies
35. Arthritis Monoclonal Antibodies Market High Potential Countries, Segments and Strategies
36. Appendix
Executive Summary
Arthritis Monoclonal Antibodies Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on arthritis monoclonal antibodies market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for arthritis monoclonal antibodies ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The arthritis monoclonal antibodies market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include: the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Drug: Remicade; Humira; Enbrel; Rituxan; Orencia; Actemra; Simponi; Cimzia; Remsima2) By Application: Rheumatoid Arthritis; Osteoarthritis; Psoriatic Arthritis; Ankylosing Spondylitis; Fibromyalgia; Other Applications
3) By End-Use: Hospitals; Research Institutes; Other End-Users
Subsegments:
Key Companies Mentioned: Johnson & Johnson; Hoffmann-La Roche Ltd.; Novartis AG; Pfizer Inc.; AbbVie Inc.Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
The major companies featured in this Arthritis Monoclonal Antibodies market report include:- Johnson & Johnson
- Hoffmann-La Roche Ltd.
- Novartis AG
- Pfizer Inc.
- AbbVie Inc.
- Amgen Inc.
- Genentech Inc.
- GlaxoSmithKline plc.
- AstraZeneca plc
- Bristol Myers Squibb
- Eli Lilly and Company
- Thermo Fisher Scientific Inc.
- Sanofi SA
- Daiichi Sankyo Company Ltd.
- Seattle Genetics
- Teva Pharmaceutical Industries Ltd.
- Shanghai Junshi Biosciences Co. Ltd.
- GenScript Biotech Corporation
- Sigma-Aldrich Co. LLC
- AbGenomics Corp.
- ADC Therapeutics SA
- Agensys Inc.
- Alexion Pharmaceuticals Inc.
- ALMAC Group Ltd.
- Ambrx Inc.
- Astellas Pharma Inc.
- Celgene Corporation
- Celldex Therapeutics Inc.
- Boehringer Ingelheim International GmbH
- Celltrion Inc.
- HanAll Biopharma Co. Ltd.
- Merck & Co. Inc.
- Mitsubishi Tanabe Pharma Corporation
- Regeneron Pharmaceuticals Inc.
- Samsung Bioepis Co. Ltd.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | April 2025 |
| Forecast Period | 2025 - 2029 |
| Estimated Market Value ( USD | $ 62.29 Billion |
| Forecasted Market Value ( USD | $ 83.76 Billion |
| Compound Annual Growth Rate | 7.7% |
| Regions Covered | Global |
| No. of Companies Mentioned | 36 |
